Literature DB >> 18637893

Effect of atorvastatin on hs-CRP in acute coronary syndrome.

Ankur Gupta1, Dinesh K Badyal, Prem P Khosla, Bharti Uppal, Thannikot M Jaison, Sandeep Chopra.   

Abstract

AIMS: To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS.
METHODS: Group A (n = 50) patients received atorvastatin 20 mg day(-1) for 4 weeks in addition to standard anti-anginal treatment. Group B (n = 50) patients received standard anti-anginal treatment without atorvastatin.
RESULTS: hs-CRP concentrations decreased in both groups, but the decrease was greater in group A. The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin.
CONCLUSIONS: The use of a lower dose (20 mg) of atorvastatin can offer an attractive approach for early treatment of patients with ACS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637893      PMCID: PMC2526247          DOI: 10.1111/j.1365-2125.2008.03172.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

Review 2.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-11-11       Impact factor: 29.690

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Authors:  I Jialal; D Stein; D Balis; S M Grundy; B Adams-Huet; S Devaraj
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

Review 5.  A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.

Authors:  Taral N Patel; Mehdi H Shishehbor; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

6.  C-reactive protein levels and outcomes after statin therapy.

Authors:  Paul M Ridker; Christopher P Cannon; David Morrow; Nader Rifai; Lynda M Rose; Carolyn H McCabe; Marc A Pfeffer; Eugene Braunwald
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

7.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

Review 8.  C-reactive protein and other inflammatory risk markers in acute coronary syndromes.

Authors:  Gavin J Blake; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

9.  An epidemiologic study of acute coronary syndromes in northwestern Greece.

Authors:  A I Papathanasiou; K D Pappas; P Korantzopoulos; J P Leontaridis; T G Vougiouklakis; M Kyrgiou; V Dimitroula; L K Michalis; J A Goudevenos
Journal:  Angiology       Date:  2004 Mar-Apr       Impact factor: 3.619

  9 in total
  3 in total

1.  Drug-induced long QT syndrome and drug development.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

2.  Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction.

Authors:  Olga Gruzdeva; Evgenya Uchasova; Yulia Dyleva; Olga Akbasheva; Victoria Karetnikova; Olga Barbarash
Journal:  Front Pharmacol       Date:  2016-09-26       Impact factor: 5.810

3.  Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.

Authors:  Debabrata Roy; Tanmay Mahapatra; Kaushik Manna; Ayan Kar; Md Saiyed Rana; Abhishek Roy; Pallab Kumar Bose; Barnali Banerjee; Srutarshi Paul; Sandipta Chakraborty
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.